Structural Basis for the Neurotropic AAV9 and the Engineered AAVPHP.eB Recognition with Cellular Receptors

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2022 Jun 27

PMID 35755945

Authors

Guangxue Xu

Ran Zhang

Huapeng Li

Kaixin Yin

Xinyi Ma

Zhiyong Lou

Affiliations

Soon will be listed here.

Abstract

Clade F adeno-associated virus (AAV) 9 has been utilized as therapeutic gene delivery vector, and it is capable of crossing blood brain barrier (BBB). Recently, an AAV9-based engineering serotype AAVPHP.eB with enhanced BBB crossing ability further expanded clade F AAVs' usages in the murine central nervous system (CNS) gene delivery. In this study, we determined the cryo-electron microscopy (cryo-EM) structures of the AAVPHP.eB and its parental serotype AAV9 in native form or in complex with their essential receptor AAV receptor (AAVR). These structures reveal the molecular details of their AAVR recognition, where the polycystic kidney disease repeat domain 2 (PKD2) of AAVR interacts with AAV9 and AAVPHP.eB virions at the 3-fold protrusions and the raised capsid regions between the 2- and 5-fold axes, termed the 2/5-fold wall. The interacting patterns of AAVR to AAV9 and AAVPHP.eB are similar to what was observed in AAV1/AAV2-AAVR complexes. Moreover, we found that the AAVPHP.eB variable region VIII (VR-VIII) may independently facilitate the new receptor recognition responsible for enhanced CNS transduction. Our study provides insights into the recognition principles of multiple receptors for engineered AAVPHP.eB and parental serotype AAV9, and further reveal the potential molecular basis underlying their different tropisms.

Citing Articles

An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species.

Vu Hong A, Suel L, Petat E, Dubois A, Le Brun P, Guerchet N Nat Commun. 2024; 15(1):7965.

PMID: 39261465 PMC: 11390886. DOI: 10.1038/s41467-024-52002-4.

Human cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder.

Shay T, Jang S, Brittain T, Chen X, Walker B, Tebbutt C Nat Commun. 2024; 15(1):7853.

PMID: 39245720 PMC: 11381518. DOI: 10.1038/s41467-024-52149-0.

Quantification of full and empty particles of adeno-associated virus vectors via a novel dual fluorescence-linked immunosorbent assay.

Soth S, Takakura M, Suekawa M, Onishi T, Hirohata K, Hashimoto T Mol Ther Methods Clin Dev. 2024; 32(3):101291.

PMID: 39070291 PMC: 11283060. DOI: 10.1016/j.omtm.2024.101291.

Unlocking precision gene therapy: harnessing AAV tropism with nanobody swapping at capsid hotspots.

Hoffmann M, Gallant J, LeBeau A, Schmidt D NAR Mol Med. 2024; 1(3):ugae008.

PMID: 39022346 PMC: 11250487. DOI: 10.1093/narmme/ugae008.

Treatment of glutaric aciduria type I (GA-I) via intracerebroventricular delivery of GCDH.

Guo L, Li Z, Li Y, Qu B, Jiao G, Liang C Fundam Res. 2024; 2(6):836-842.

PMID: 38933374 PMC: 11197790. DOI: 10.1016/j.fmre.2022.08.013.

References

Zhang R, Xu G, Cao L, Sun Z, He Y, Cui M . Divergent engagements between adeno-associated viruses with their cellular receptor AAVR. Nat Commun. 2019; 10(1):3760. PMC: 6704107. DOI: 10.1038/s41467-019-11668-x. View

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

Terstappen G, Meyer A, Bell R, Zhang W . Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021; 20(5):362-383. DOI: 10.1038/s41573-021-00139-y. View

Martino R, Fluck 3rd E, Murphy J, Wang Q, Hoff H, Pumroy R . Context-Specific Function of the Engineered Peptide Domain of PHP.B. J Virol. 2021; 95(20):e0116421. PMC: 8475521. DOI: 10.1128/JVI.01164-21. View

Hu M, Yu H, Gu K, Wang Z, Ruan H, Wang K . A particle-filter framework for robust cryo-EM 3D reconstruction. Nat Methods. 2018; 15(12):1083-1089. DOI: 10.1038/s41592-018-0223-8. View

Shen S, Bryant K, Brown S, Randell S, Asokan A . Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem. 2011; 286(15):13532-40. PMC: 3075699. DOI: 10.1074/jbc.M110.210922. View

Zhang R, Cao L, Cui M, Sun Z, Hu M, Zhang R . Adeno-associated virus 2 bound to its cellular receptor AAVR. Nat Microbiol. 2019; 4(4):675-682. DOI: 10.1038/s41564-018-0356-7. View

Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg J . Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov. 2013; 12(9):719. DOI: 10.1038/nrd3835-c1. View

10.

Adachi K, Enoki T, Kawano Y, Veraz M, Nakai H . Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat Commun. 2014; 5:3075. PMC: 3941020. DOI: 10.1038/ncomms4075. View

11.

Russell S, Bennett J, Wellman J, Chung D, Yu Z, Tillman A . Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017; 390(10097):849-860. PMC: 5726391. DOI: 10.1016/S0140-6736(17)31868-8. View

12.

Mietzsch M, Smith J, Yu J, Banala V, Emmanuel S, Jose A . Characterization of AAV-Specific Affinity Ligands: Consequences for Vector Purification and Development Strategies. Mol Ther Methods Clin Dev. 2020; 19:362-373. PMC: 7591348. DOI: 10.1016/j.omtm.2020.10.001. View

13.

Dhungel B, Bailey C, Rasko J . Journey to the Center of the Cell: Tracing the Path of AAV Transduction. Trends Mol Med. 2020; 27(2):172-184. DOI: 10.1016/j.molmed.2020.09.010. View

14.

Scheres S . RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012; 180(3):519-30. PMC: 3690530. DOI: 10.1016/j.jsb.2012.09.006. View

15.

Meyer N, Hu G, Davulcu O, Xie Q, Noble A, Yoshioka C . Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR. Elife. 2019; 8. PMC: 6561701. DOI: 10.7554/eLife.44707. View

16.

Penzes J, Chipman P, Bhattacharya N, Zeher A, Huang R, McKenna R . Adeno-associated Virus 9 Structural Rearrangements Induced by Endosomal Trafficking pH and Glycan Attachment. J Virol. 2021; 95(19):e0084321. PMC: 8428384. DOI: 10.1128/JVI.00843-21. View

17.

Pedelacq J, Cabantous S, Tran T, Terwilliger T, Waldo G . Engineering and characterization of a superfolder green fluorescent protein. Nat Biotechnol. 2005; 24(1):79-88. DOI: 10.1038/nbt1172. View

18.

Pillay S, Meyer N, Puschnik A, Davulcu O, Diep J, Ishikawa Y . An essential receptor for adeno-associated virus infection. Nature. 2016; 530(7588):108-12. PMC: 4962915. DOI: 10.1038/nature16465. View

19.

Rohou A, Grigorieff N . CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015; 192(2):216-21. PMC: 6760662. DOI: 10.1016/j.jsb.2015.08.008. View

20.

Bell C, Gurda B, Van Vliet K, Agbandje-Mckenna M, Wilson J . Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol. 2012; 86(13):7326-33. PMC: 3416318. DOI: 10.1128/JVI.00448-12. View